NOVO NORDISK A S
NONOFDrugs in Pipeline
52
Phase 3 Programs
42
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
insulin degludec
Diabetes
Cagrilintide
Obesity
insulin aspart
Diabetes
liraglutide
Diabetes
insulin degludec/liraglutide
Diabetes
Mim8
Haemophilia A With or Without Inhibitors
rosiglitazone
Diabetes
insulin degludec/insulin aspart
Diabetes
Ziltivekimab
Cardiovascular Risk
biphasic insulin aspart
Diabetes
Tirzepatide
Obesity
IcoSema
Diabetes Mellitus, Type 2
Concizumab
Haemophilia A With Inhibitors
NNC0487-0111
Obesity
estradiol, 10 mcg
Menopause
Norditropin®
SGA, Turner Syndrome, Noonan Syndrome, ISS
biphasic insulin aspart 50
Diabetes
pioglitazone
Diabetes
semaglutide 2.4 mg
Obesity
activated recombinant human factor VII
Acquired Bleeding Disorder
Insulin Icodec
Diabetes Mellitus, Type 2
biphasic human insulin
Diabetes
Semaglutide
Diabetes Mellitus, Type 2
catridecacog
Congenital Bleeding Disorder
Turoctocog alfa pegol
Congenital Bleeding Disorder
Somapacitan
Growth Hormone Deficiency in Children
insulin detemir
Diabetes
metformin
Diabetes
insulin glargine
Diabetes
sitagliptin
Diabetes
biphasic insulin aspart 30
Diabetes
NPH insulin
Diabetes Mellitus, Type 1
Faster-acting insulin aspart
Diabetes
insulin NPH
Diabetes
Nonacog beta pegol
Haemophilia B
glimepiride
Diabetes
biphasic insulin aspart 70
Diabetes
turoctocog alfa
Congenital Bleeding Disorder
Oral semaglutide
Obesity
somatropin
Growth Hormone Disorder
Dulaglutide
Diabetes
exenatide
Diabetes
NNC126-0083
Growth Hormone Disorder
eptacog alfa (activated)
Acquired Bleeding Disorder
NNC0114-0006
Inflammation
CagriSema (Cagrilintide B and Semaglutide I)
Diabetes Mellitus, Type 2
NNC0519-0130
Obesity
NNC0662-0419
Diabetes Mellitus, Type 2
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Etavopivat
Sickle Cell Disease
DCR-PHXC
Primary Hyperoxaluria Type 1
Insulin glargine U100
Diabetes Mellitus, Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
insulin degludec | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A With or Without Inhibitors | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
Ziltivekimab | Phase 3 | Cardiovascular Risk | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Tirzepatide | Phase 3 | Obesity | - | - |
IcoSema | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Concizumab | Phase 3 | Haemophilia A With Inhibitors | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
estradiol, 10 mcg | Phase 3 | Menopause | - | - |
Norditropin® | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
pioglitazone | Phase 3 | Diabetes | - | - |
semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
Turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
Somapacitan | Phase 3 | Growth Hormone Deficiency in Children | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
metformin | Phase 3 | Diabetes | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
sitagliptin | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
NPH insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
Nonacog beta pegol | Phase 3 | Haemophilia B | - | - |
glimepiride | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
turoctocog alfa | Phase 3 | Congenital Bleeding Disorder | - | - |
Oral semaglutide | Phase 3 | Obesity | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
Dulaglutide | Phase 3 | Diabetes | - | - |
exenatide | Phase 3 | Diabetes | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
eptacog alfa (activated) | Phase 2 | Acquired Bleeding Disorder | - | - |
NNC0114-0006 | Phase 2 | Inflammation | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC0519-0130 | Phase 2 | Obesity | - | - |
NNC0662-0419 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC6019-0001 | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
DCR-PHXC | Phase 2 | Primary Hyperoxaluria Type 1 | - | - |
Insulin glargine U100 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |